{"transactions":[{"id":2932248,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-qualified Stock Option (right to buy)","published_at":"2020-12-29T00:21:18.000Z","date":"2020-12-22","kind":"exercise","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":1.4,"exercise_date":"2020-12-22","expiration_date":"2022-12-13","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001807094-20-000031","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000031/primary_doc.xml","form_type":"4"}},{"id":2932247,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-qualified Stock Option (right to buy)","published_at":"2020-12-29T00:21:18.000Z","date":"2020-12-22","kind":"exercise","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":1.09,"exercise_date":"2020-12-22","expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001807094-20-000031","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000031/primary_doc.xml","form_type":"4"}},{"id":2932246,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-qualified Stock Option (right to buy)","published_at":"2020-12-29T00:21:18.000Z","date":"2020-12-22","kind":"exercise","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.9,"exercise_date":"2020-12-22","expiration_date":"2025-06-30","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001807094-20-000031","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000031/primary_doc.xml","form_type":"4"}},{"id":2932245,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-qualified Stock Option (right to buy)","published_at":"2020-12-29T00:21:18.000Z","date":"2020-12-22","kind":"exercise","acquired":true,"shares":161801,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.87,"exercise_date":"2020-12-22","expiration_date":"2025-11-23","underlying":"Common Stock","underlying_shares":161801},"source":{"system":"sec-edgar","filing":"0001807094-20-000031","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000031/primary_doc.xml","form_type":"4"}},{"id":2932244,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-29T00:21:18.000Z","date":"2020-12-22","kind":"sale","acquired":false,"shares":12100,"price":7,"value":84700.0,"ownership":{"direct":true},"balance_after":284081,"source":{"system":"sec-edgar","filing":"0001807094-20-000031","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000031/primary_doc.xml","form_type":"4"}},{"id":2932243,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-29T00:21:18.000Z","date":"2020-12-22","kind":"sale","acquired":false,"shares":453997,"price":6.6146,"value":3003008.5562,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $6.02 to $6.99. The price above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":296181,"source":{"system":"sec-edgar","filing":"0001807094-20-000031","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000031/primary_doc.xml","form_type":"4"}},{"id":2932242,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-29T00:21:18.000Z","date":"2020-12-22","kind":"sale","acquired":false,"shares":245704,"price":5.4938,"value":1349848.6352,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale transactions reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan the Reporting Person entered into on November 12, 2020. The plan provides for the periodic sales by the Reporting Person's broker without further action by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $5.03 to $5.98. The price above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":750178,"source":{"system":"sec-edgar","filing":"0001807094-20-000031","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000031/primary_doc.xml","form_type":"4"}},{"id":2932241,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-29T00:21:18.000Z","date":"2020-12-22","kind":"exercise","acquired":true,"shares":100000,"price":1.4,"value":140000.0,"ownership":{"direct":true},"balance_after":995882,"source":{"system":"sec-edgar","filing":"0001807094-20-000031","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000031/primary_doc.xml","form_type":"4"}},{"id":2932240,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-29T00:21:18.000Z","date":"2020-12-22","kind":"exercise","acquired":true,"shares":300000,"price":1.09,"value":327000.0,"ownership":{"direct":true},"balance_after":895882,"source":{"system":"sec-edgar","filing":"0001807094-20-000031","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000031/primary_doc.xml","form_type":"4"}},{"id":2932239,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-29T00:21:18.000Z","date":"2020-12-22","kind":"exercise","acquired":true,"shares":150000,"price":0.9,"value":135000.0,"ownership":{"direct":true},"balance_after":595882,"source":{"system":"sec-edgar","filing":"0001807094-20-000031","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000031/primary_doc.xml","form_type":"4"}},{"id":2932238,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-29T00:21:18.000Z","date":"2020-12-22","kind":"exercise","acquired":true,"shares":161801,"price":0.87,"value":140766.87,"ownership":{"direct":true},"balance_after":445882,"source":{"system":"sec-edgar","filing":"0001807094-20-000031","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000031/primary_doc.xml","form_type":"4"}},{"id":2937051,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-qualified Stock Option (right to buy)","published_at":"2020-12-22T02:55:52.000Z","date":"2020-12-21","kind":"exercise","acquired":true,"shares":88199,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Fifty percent (50%) of the reported option became fully vested in 2016 and 50% was forfeited."}],"balance_after":161801,"derivative":{"exercise_price":0.87,"exercise_date":"2020-12-21","expiration_date":"2025-11-23","underlying":"Common Stock","underlying_shares":88199},"source":{"system":"sec-edgar","filing":"0001807094-20-000030","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000030/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-12-21"}},{"id":2937050,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-qualified Stock Option (right to buy)","published_at":"2020-12-22T02:55:52.000Z","date":"2020-12-21","kind":"exercise","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The reported option became fully vested on grant date."}],"balance_after":0,"derivative":{"exercise_price":0.8,"exercise_date":"2020-12-21","expiration_date":"2023-02-15","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001807094-20-000030","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000030/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-12-21"}},{"id":2937049,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-qualified Stock Option (right to buy)","published_at":"2020-12-22T02:55:52.000Z","date":"2020-12-21","kind":"exercise","acquired":true,"shares":201598,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.57,"exercise_date":"2020-12-21","expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":201598},"source":{"system":"sec-edgar","filing":"0001807094-20-000030","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000030/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-12-21"}},{"id":2937048,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-qualified Stock Option (right to buy)","published_at":"2020-12-22T02:55:52.000Z","date":"2020-12-18","kind":"exercise","acquired":true,"shares":98402,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The reported option became fully vested on June 1, 2020."}],"balance_after":201598,"derivative":{"exercise_price":0.57,"exercise_date":"2020-12-18","expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":98402},"source":{"system":"sec-edgar","filing":"0001807094-20-000030","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000030/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-12-21"}},{"id":2937047,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-qualified Stock Option (right to buy)","published_at":"2020-12-22T02:55:52.000Z","date":"2020-12-18","kind":"exercise","acquired":true,"shares":233100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Sixty-seven percent (67%) of the reported option became fully vested on June 8, 2020; the shares remaining subject to this option vest on June 8, 2021."}],"balance_after":116900,"derivative":{"exercise_price":0.49,"exercise_date":"2020-12-18","expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":233100},"source":{"system":"sec-edgar","filing":"0001807094-20-000030","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000030/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-12-21"}},{"id":2937046,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-qualified Stock Option (right to buy)","published_at":"2020-12-22T02:55:52.000Z","date":"2020-12-18","kind":"exercise","acquired":true,"shares":155500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.39,"exercise_date":"2020-12-18","expiration_date":"2029-10-07","underlying":"Common Stock","underlying_shares":155500},"source":{"system":"sec-edgar","filing":"0001807094-20-000030","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000030/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-12-21"}},{"id":2937045,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-qualified Stock Option (right to buy)","published_at":"2020-12-22T02:55:52.000Z","date":"2020-12-17","kind":"exercise","acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The reported option became fully vested on October 7, 2020."}],"balance_after":155500,"derivative":{"exercise_price":0.39,"exercise_date":"2020-12-17","expiration_date":"2029-10-07","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001807094-20-000030","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000030/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-12-21"}},{"id":2937044,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-22T02:55:52.000Z","date":"2020-12-21","kind":"sale","acquired":false,"shares":585797,"price":5.582,"value":3269918.854,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $5.03 to $6.00. The price above reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":284081,"source":{"system":"sec-edgar","filing":"0001807094-20-000030","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000030/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-12-21"}},{"id":2937043,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-22T02:55:52.000Z","date":"2020-12-21","kind":"exercise","acquired":true,"shares":88199,"price":0.87,"value":76733.13,"ownership":{"direct":true},"balance_after":873878,"source":{"system":"sec-edgar","filing":"0001807094-20-000030","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000030/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-12-21"}},{"id":2937042,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-22T02:55:52.000Z","date":"2020-12-21","kind":"exercise","acquired":true,"shares":300000,"price":0.8,"value":240000.0,"ownership":{"direct":true},"balance_after":785679,"source":{"system":"sec-edgar","filing":"0001807094-20-000030","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000030/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-12-21"}},{"id":2937041,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-22T02:55:52.000Z","date":"2020-12-21","kind":"exercise","acquired":true,"shares":201598,"price":0.57,"value":114910.86,"ownership":{"direct":true},"balance_after":485679,"source":{"system":"sec-edgar","filing":"0001807094-20-000030","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000030/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-12-21"}},{"id":2937040,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-22T02:55:52.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":487002,"price":4.9516,"value":2411439.1032,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $4.80 to $5.08. The price above reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":284081,"source":{"system":"sec-edgar","filing":"0001807094-20-000030","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000030/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-12-21"}},{"id":2937039,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-22T02:55:52.000Z","date":"2020-12-18","kind":"exercise","acquired":true,"shares":98402,"price":0.57,"value":56089.14,"ownership":{"direct":true},"balance_after":771083,"source":{"system":"sec-edgar","filing":"0001807094-20-000030","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000030/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-12-21"}},{"id":2937038,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-22T02:55:52.000Z","date":"2020-12-18","kind":"exercise","acquired":true,"shares":233100,"price":0.49,"value":114219.0,"ownership":{"direct":true},"balance_after":672681,"source":{"system":"sec-edgar","filing":"0001807094-20-000030","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000030/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-12-21"}},{"id":2937037,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-22T02:55:52.000Z","date":"2020-12-18","kind":"exercise","acquired":true,"shares":155500,"price":0.39,"value":60645.0,"ownership":{"direct":true},"balance_after":439581,"source":{"system":"sec-edgar","filing":"0001807094-20-000030","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000030/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-12-21"}},{"id":2937036,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-22T02:55:52.000Z","date":"2020-12-17","kind":"sale","acquired":false,"shares":32000,"price":4.5523,"value":145673.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All shares sold and reported in this Form 4 were sold pursuant to a Rule 10b5-1 trading plan the reporting person entered into on November 12, 2020. The plan provides for periodic sales by the reporting person's broker without further action by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $4.50 to $4.68. The price above reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":284081,"source":{"system":"sec-edgar","filing":"0001807094-20-000030","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000030/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-12-21"}},{"id":2937035,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-22T02:55:52.000Z","date":"2020-12-17","kind":"exercise","acquired":true,"shares":32000,"price":0.39,"value":12480.0,"ownership":{"direct":true},"balance_after":316081,"source":{"system":"sec-edgar","filing":"0001807094-20-000030","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000030/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-12-21"}},{"id":2937034,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-qualified Stock Option (right to buy)","published_at":"2020-12-22T02:01:13.000Z","date":"2020-12-21","kind":"exercise","acquired":true,"shares":88199,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Fifty percent (50%) of the reported option became fully vested in 2016 and 50% was forfeited."}],"balance_after":161801,"derivative":{"exercise_price":0.87,"exercise_date":"2020-12-21","expiration_date":"2025-11-23","underlying":"Common Stock","underlying_shares":88199},"source":{"system":"sec-edgar","filing":"0001807094-20-000029","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000029/primary_doc.xml","form_type":"4"}},{"id":2937033,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-qualified Stock Option (right to buy)","published_at":"2020-12-22T02:01:13.000Z","date":"2020-12-21","kind":"exercise","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The reported option became fully vested on grant date."}],"balance_after":0,"derivative":{"exercise_price":0.8,"exercise_date":"2020-12-21","expiration_date":"2023-02-15","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001807094-20-000029","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000029/primary_doc.xml","form_type":"4"}},{"id":2937032,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-qualified Stock Option (right to buy)","published_at":"2020-12-22T02:01:13.000Z","date":"2020-12-21","kind":"exercise","acquired":true,"shares":201598,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.57,"exercise_date":"2020-12-21","expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":201598},"source":{"system":"sec-edgar","filing":"0001807094-20-000029","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000029/primary_doc.xml","form_type":"4"}},{"id":2937031,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-qualified Stock Option (right to buy)","published_at":"2020-12-22T02:01:13.000Z","date":"2020-12-18","kind":"exercise","acquired":true,"shares":98402,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The reported option became fully vested on June 1, 2020."}],"balance_after":201598,"derivative":{"exercise_price":0.57,"exercise_date":"2020-12-18","expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":98402},"source":{"system":"sec-edgar","filing":"0001807094-20-000029","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000029/primary_doc.xml","form_type":"4"}},{"id":2937030,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-qualified Stock Option (right to buy)","published_at":"2020-12-22T02:01:13.000Z","date":"2020-12-18","kind":"exercise","acquired":true,"shares":233100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Sixty-seven percent (67%) of the reported option became fully vested on June 8, 2020; the shares remaining subject to this option vest on June 8, 2021."}],"balance_after":116900,"derivative":{"exercise_price":0.49,"exercise_date":"2020-12-18","expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":233100},"source":{"system":"sec-edgar","filing":"0001807094-20-000029","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000029/primary_doc.xml","form_type":"4"}},{"id":2937029,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-qualified Stock Option (right to buy)","published_at":"2020-12-22T02:01:13.000Z","date":"2020-12-18","kind":"exercise","acquired":true,"shares":155500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.39,"exercise_date":"2020-12-18","expiration_date":"2029-10-07","underlying":"Common Stock","underlying_shares":155500},"source":{"system":"sec-edgar","filing":"0001807094-20-000029","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000029/primary_doc.xml","form_type":"4"}},{"id":2937028,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-qualified Stock Option (right to buy)","published_at":"2020-12-22T02:01:13.000Z","date":"2020-12-17","kind":"exercise","acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The reported option became fully vested on October 7, 2020."}],"balance_after":155500,"derivative":{"exercise_price":0.39,"exercise_date":"2020-12-17","expiration_date":"2029-10-07","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001807094-20-000029","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000029/primary_doc.xml","form_type":"4"}},{"id":2937027,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-22T02:01:13.000Z","date":"2020-12-21","kind":"sale","acquired":false,"shares":589797,"price":5.582,"value":3292246.854,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $5.03 to $6.00. The price above reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":284081,"source":{"system":"sec-edgar","filing":"0001807094-20-000029","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000029/primary_doc.xml","form_type":"4"}},{"id":2937026,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-22T02:01:13.000Z","date":"2020-12-21","kind":"exercise","acquired":true,"shares":88199,"price":0.87,"value":76733.13,"ownership":{"direct":true},"balance_after":873878,"source":{"system":"sec-edgar","filing":"0001807094-20-000029","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000029/primary_doc.xml","form_type":"4"}},{"id":2937025,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-22T02:01:13.000Z","date":"2020-12-21","kind":"exercise","acquired":true,"shares":300000,"price":0.8,"value":240000.0,"ownership":{"direct":true},"balance_after":785679,"source":{"system":"sec-edgar","filing":"0001807094-20-000029","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000029/primary_doc.xml","form_type":"4"}},{"id":2937024,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-22T02:01:13.000Z","date":"2020-12-21","kind":"exercise","acquired":true,"shares":201598,"price":0.57,"value":114910.86,"ownership":{"direct":true},"balance_after":485679,"source":{"system":"sec-edgar","filing":"0001807094-20-000029","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000029/primary_doc.xml","form_type":"4"}},{"id":2937023,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-22T02:01:13.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":487002,"price":4.9516,"value":2411439.1032,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $4.80 to $5.08. The price above reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":284081,"source":{"system":"sec-edgar","filing":"0001807094-20-000029","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000029/primary_doc.xml","form_type":"4"}},{"id":2937022,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-22T02:01:13.000Z","date":"2020-12-18","kind":"exercise","acquired":true,"shares":98402,"price":0.57,"value":56089.14,"ownership":{"direct":true},"balance_after":771083,"source":{"system":"sec-edgar","filing":"0001807094-20-000029","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000029/primary_doc.xml","form_type":"4"}},{"id":2937021,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-22T02:01:13.000Z","date":"2020-12-18","kind":"exercise","acquired":true,"shares":233100,"price":0.49,"value":114219.0,"ownership":{"direct":true},"balance_after":672681,"source":{"system":"sec-edgar","filing":"0001807094-20-000029","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000029/primary_doc.xml","form_type":"4"}},{"id":2937020,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-22T02:01:13.000Z","date":"2020-12-18","kind":"exercise","acquired":true,"shares":155500,"price":0.39,"value":60645.0,"ownership":{"direct":true},"balance_after":439581,"source":{"system":"sec-edgar","filing":"0001807094-20-000029","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000029/primary_doc.xml","form_type":"4"}},{"id":2937019,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-22T02:01:13.000Z","date":"2020-12-17","kind":"sale","acquired":false,"shares":32000,"price":4.5523,"value":145673.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All shares sold and reported in this Form 4 were sold pursuant to a Rule 10b5-1 trading plan the reporting person entered into on November 12, 2020. The plan provides for periodic sales by the reporting person's broker without further action by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $4.50 to $4.68. The price above reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and price at which the transaction was effected."}],"balance_after":284081,"source":{"system":"sec-edgar","filing":"0001807094-20-000029","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000029/primary_doc.xml","form_type":"4"}},{"id":2937018,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-22T02:01:13.000Z","date":"2020-12-17","kind":"exercise","acquired":true,"shares":32000,"price":0.39,"value":12480.0,"ownership":{"direct":true},"balance_after":316081,"source":{"system":"sec-edgar","filing":"0001807094-20-000029","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000029/primary_doc.xml","form_type":"4"}},{"id":3017775,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-qualified Stock Option","published_at":"2020-10-02T22:26:54.000Z","date":"2020-09-30","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"The option grant was approved by a committee of the Issuer's Board of Directors on June 15, 2020, subject to stockholder approval of the Issuer's Amended & Restated 2012 Equity Incentive Plan (the \"Plan\") under which the option was granted. The Issuer's stockholders approved the Plan on September 30, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests annually in three equal installments beginning June 15, 2021."}],"balance_after":200000,"derivative":{"exercise_price":3.12,"expiration_date":"2030-06-15","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001807094-20-000019","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000019/primary_doc.xml","form_type":"4"}},{"id":3017774,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-10-02T22:26:54.000Z","date":"2020-09-30","kind":"grant","acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Amended & Restated 2012 Equity Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."}],"balance_after":284081,"source":{"system":"sec-edgar","filing":"0001807094-20-000019","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000019/primary_doc.xml","form_type":"4"}},{"id":3330767,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-Finance"}}],"security":"Common Stock","published_at":"2019-12-28T01:00:17.000Z","date":"2019-12-24","kind":"tax_withholding","acquired":false,"shares":56942,"price":0.64,"value":36442.88,"ownership":{"direct":true},"balance_after":184081,"source":{"system":"sec-edgar","filing":"0000899243-19-030131","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319030131/doc4.xml","form_type":"4"}},{"id":3330766,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-Finance"}}],"security":"Common Stock","published_at":"2019-12-28T01:00:17.000Z","date":"2019-12-24","kind":"grant","acquired":true,"shares":153897,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were granted in respect of an annual performance award for the fiscal year ended May 31, 2018, which had been previously approved but not yet issued."}],"balance_after":241023,"source":{"system":"sec-edgar","filing":"0000899243-19-030131","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319030131/doc4.xml","form_type":"4"}},{"id":3333444,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2019-12-24T00:11:05.000Z","date":"2019-12-19","kind":"grant","acquired":true,"shares":700000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-half of the options vest immediately upon grant and one-half of the options will vest upon the achievement of certain additional strategic milestones specified in the award agreement."}],"balance_after":700000,"derivative":{"exercise_price":0.63,"expiration_date":"2029-12-19","underlying":"Common Stock","underlying_shares":700000},"source":{"system":"sec-edgar","filing":"0000899243-19-030008","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319030008/doc4.xml","form_type":"4"}},{"id":3394974,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Stock Options (right to buy)","published_at":"2019-10-11T01:44:14.000Z","date":"2019-10-07","kind":"grant","acquired":true,"shares":187500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This report is being filed to correct an inadvertent error, to report the options issued October 7, 2019 as acquired (and not disposed of) in the transaction, in Column 5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest in twelve equal monthly installments over the one year period commencing on November 7, 2019"}],"balance_after":187500,"derivative":{"exercise_price":0.39,"expiration_date":"2029-10-07","underlying":"Common Stock","underlying_shares":187500},"source":{"system":"sec-edgar","filing":"0000899243-19-025493","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319025493/doc4a.xml","form_type":"4/A","original_submission_date":"2019-10-08"}},{"id":3396382,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Stock Options (right to buy)","published_at":"2019-10-08T23:05:14.000Z","date":"2019-10-07","kind":"grant","acquired":false,"shares":187500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in twelve equal monthly installments over the one year period commencing on November 7, 2019"}],"balance_after":187500,"derivative":{"exercise_price":0.39,"expiration_date":"2029-10-07","underlying":"Common Stock","underlying_shares":187500},"source":{"system":"sec-edgar","filing":"0000899243-19-025315","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319025315/doc4.xml","form_type":"4"}},{"id":3760357,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:02:15.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":350000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options vest in three equal annual installments commencing on June 1, 2019."}],"balance_after":350000,"derivative":{"exercise_price":0.49,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0000899243-18-029258","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029258/doc4.xml","form_type":"4"}},{"id":3760356,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:02:15.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":300000,"derivative":{"exercise_price":0.8,"exercise_date":"2018-02-15","expiration_date":"2023-05-31","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0000899243-18-029258","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029258/doc4.xml","form_type":"4"}},{"id":3760355,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:02:15.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options (including predecessor options) vest in three equal annual installments commencing on June 1, 2018."}],"balance_after":300000,"derivative":{"exercise_price":0.57,"expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0000899243-18-029258","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029258/doc4.xml","form_type":"4"}},{"id":3760354,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:02:15.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options (including predecessor options) vest in three equal annual installments commencing on June 1, 2017."}],"balance_after":300000,"derivative":{"exercise_price":1.09,"expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0000899243-18-029258","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029258/doc4.xml","form_type":"4"}},{"id":3760353,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:02:15.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options (including predecessor options) vest upon the achievement of certain strategic milestones specified in the award agreement."}],"balance_after":500000,"derivative":{"exercise_price":0.87,"expiration_date":"2025-11-23","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000899243-18-029258","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029258/doc4.xml","form_type":"4"}},{"id":3760352,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:02:15.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":150000,"derivative":{"exercise_price":0.9,"exercise_date":"2018-06-30","expiration_date":"2025-06-30","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000899243-18-029258","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029258/doc4.xml","form_type":"4"}},{"id":3760351,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:02:15.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":150000,"derivative":{"exercise_price":0.64,"exercise_date":"2018-05-29","expiration_date":"2019-05-29","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000899243-18-029258","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029258/doc4.xml","form_type":"4"}},{"id":3760350,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:02:15.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":100000,"derivative":{"exercise_price":1.4,"exercise_date":"2015-12-13","expiration_date":"2022-12-13","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-18-029258","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029258/doc4.xml","form_type":"4"}},{"id":3760349,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Common Stock","published_at":"2018-11-19T13:02:15.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":87126,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":87126,"source":{"system":"sec-edgar","filing":"0000899243-18-029258","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029258/doc4.xml","form_type":"4"}},{"id":3762667,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:31:20.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":350000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options vest in three equal annual installments commencing on June 1, 2019."}],"balance_after":0,"derivative":{"exercise_price":0.49,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0000899243-18-029190","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029190/doc4.xml","form_type":"4"}},{"id":3762666,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:31:20.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.8,"exercise_date":"2018-02-15","expiration_date":"2023-05-31","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0000899243-18-029190","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029190/doc4.xml","form_type":"4"}},{"id":3762665,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:31:20.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vest in three equal annual installments commencing on June 1, 2018."}],"balance_after":0,"derivative":{"exercise_price":0.57,"expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0000899243-18-029190","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029190/doc4.xml","form_type":"4"}},{"id":3762664,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:31:20.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest in three equal annual installments commencing on June 1, 2017."}],"balance_after":0,"derivative":{"exercise_price":1.09,"expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0000899243-18-029190","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029190/doc4.xml","form_type":"4"}},{"id":3762663,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:31:20.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest upon the achievement of certain strategic milestones specified in the award agreement."}],"balance_after":0,"derivative":{"exercise_price":0.87,"expiration_date":"2025-11-23","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000899243-18-029190","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029190/doc4.xml","form_type":"4"}},{"id":3762662,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:31:20.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.9,"exercise_date":"2018-06-30","expiration_date":"2025-06-30","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000899243-18-029190","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029190/doc4.xml","form_type":"4"}},{"id":3762661,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:31:20.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.64,"exercise_date":"2018-05-29","expiration_date":"2019-05-29","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000899243-18-029190","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029190/doc4.xml","form_type":"4"}},{"id":3762660,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:31:20.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":1.4,"exercise_date":"2015-12-13","expiration_date":"2022-12-13","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-18-029190","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029190/doc4.xml","form_type":"4"}},{"id":3762659,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Common Stock","published_at":"2018-11-16T23:31:20.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":87126,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-029190","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029190/doc4.xml","form_type":"4"}},{"id":3897816,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Stock Options (right to buy)","published_at":"2018-06-12T22:02:59.000Z","date":"2018-06-08","kind":"grant","acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in three equal annual installments commencing on June 8, 2019."}],"balance_after":350000,"derivative":{"exercise_price":0.49,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0000899243-18-016242","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318016242/doc4.xml","form_type":"4"}},{"id":3988622,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Common Stock","published_at":"2018-03-20T10:05:46.000Z","date":"2018-03-15","kind":"tax_withholding","acquired":false,"shares":38733,"price":0.69,"value":26725.77,"ownership":{"direct":true},"balance_after":87126,"source":{"system":"sec-edgar","filing":"0000899243-18-008069","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318008069/doc4.xml","form_type":"4"}},{"id":3988621,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Common Stock","published_at":"2018-03-20T10:05:46.000Z","date":"2018-03-15","kind":"grant","acquired":true,"shares":88816,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":125859,"source":{"system":"sec-edgar","filing":"0000899243-18-008069","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318008069/doc4.xml","form_type":"4"}},{"id":4053917,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Stock Options (right to buy)","published_at":"2018-02-16T23:00:33.000Z","date":"2018-02-15","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":300000,"derivative":{"exercise_price":0.8,"exercise_date":"2018-02-15","expiration_date":"2023-05-31","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0000899243-18-004432","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318004432/doc4.xml","form_type":"4"}},{"id":4053916,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Stock Options (right to buy)","published_at":"2018-02-16T23:00:33.000Z","date":"2018-02-15","kind":"disposition_to_issuer","acquired":false,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such options were fully vested and exercisable as of the date of the reported transactions."}],"balance_after":0,"derivative":{"exercise_price":0.8,"expiration_date":"2018-05-31","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0000899243-18-004432","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318004432/doc4.xml","form_type":"4"}},{"id":4294823,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Stock Options (right to buy)","published_at":"2017-06-05T20:46:15.000Z","date":"2017-06-01","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to stockholder approval, at the next annual meeting, of the increase in the number of shares of common stock authorized for issuance under the CytoDyn Inc. 2012 Equity Incentive Plan, as amended, the options will vest in three equal annual installments commencing on June 1, 2018."}],"balance_after":300000,"derivative":{"exercise_price":0.57,"expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0000899243-17-015353","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924317015353/doc4.xml","form_type":"4"}},{"id":4579428,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":144385,"kind":"person","name":"Mulholland Michael D.","position":1,"cik":"0001257911","reported_name":"Mulholland Michael D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer and Secretary"}}],"security":"Common Stock","published_at":"2016-10-17T20:01:28.000Z","date":"2016-10-17","kind":"purchase","acquired":true,"shares":11000,"price":0.658,"value":7238.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.655 to $0.66, inclusive. The reporting person undertakes to provide to CytoDyn Inc., any security holder of CytoDyn Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth herein."}],"balance_after":37043,"source":{"system":"sec-edgar","filing":"0000899243-16-031752","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924316031752/doc4.xml","form_type":"4"}}]}